A 48-year-old woman with hypertension and type 2 diabetes mellitus is prescribed metoprolol 100 mg daily. After 3 weeks, she reports persistent fatigue, inability to exercise, and a 2 kg weight gain. Her blood glucose (fasting) has increased from 110 mg/dL to 145 mg/dL. HR is 58/min (baseline 72/min), BP 128/82 mmHg. She is otherwise asymptomatic. What is the most appropriate next step in management?

Explanation

## Clinical Scenario Analysis The patient is experiencing **non-hemodynamic adverse effects** of non-selective beta-blockers: fatigue, weight gain, and **impaired glucose tolerance** (fasting glucose rise of 35 mg/dL). These are metabolic side effects, not dose-dependent toxicity, but dose reduction may improve tolerability while maintaining therapeutic benefit. ## Mechanism of Beta-Blocker–Induced Metabolic Effects ### Why Glucose Control Worsens **Key Point:** Non-selective beta-blockers (metoprolol, propranolol) **block β~2~-adrenergic receptors on pancreatic islet cells**, impairing insulin secretion and promoting hepatic glucose output. **High-Yield:** Beta-blockers are **relatively contraindicated in diabetes** because they: 1. Suppress insulin release (β~2~ blockade on pancreatic beta cells) 2. Impair counter-regulatory response to hypoglycemia (mask tachycardia warning sign) 3. Promote weight gain and fatigue (reduced sympathetic tone) ### Management Strategy **Clinical Pearl:** In patients with diabetes and hypertension, **first-line agents are ACE inhibitors, ARBs, or calcium channel blockers**—not beta-blockers. If a beta-blocker is necessary, use a **selective β~1~-blocker** (atenolol, bisoprolol) or one with **intrinsic sympathomimetic activity** (ISA, e.g., pindolol). However, the correct next step here is **dose reduction + switch to a more appropriate agent**, not continuation of the current regimen. ## Why Option 3 is Correct 1. **Dose reduction** (100 mg → 50 mg) may improve fatigue and glucose tolerance while maintaining some BP control. 2. **Switch to an alternative agent** (ACE inhibitor, ARB, or CCB) is more appropriate for a diabetic patient, as these classes improve insulin sensitivity and do not worsen glucose control. 3. This approach balances immediate symptom relief with long-term metabolic benefit. ## Why Other Options Are Incorrect | Option | Why Wrong | |--------|----------| | Switch to pindolol (ISA beta-blocker) | While ISA agents have less metabolic impact than non-selective blockers, they are still **not ideal first-line agents in diabetes**. Pindolol is rarely used in modern practice; ACE inhibitors or ARBs are superior. | | Discontinue metoprolol + ACE inhibitor monotherapy | Abrupt withdrawal risks rebound hypertension. A gradual taper is needed. Additionally, ACE inhibitor monotherapy may be insufficient for BP control in this patient; combination therapy is often required. | | Continue metoprolol + add thiazide | Thiazides **worsen glucose control** and are contraindicated in diabetes. This combination would exacerbate the metabolic problem. | **Mnemonic:** **ABCD of Hypertension in Diabetes** — ACE inhibitors, ARBs, Calcium channel blockers, Diuretics (cautiously). Beta-blockers are **not first-line** in diabetic hypertension. **Warning:** Do not confuse **dose-dependent adverse effects** (bradycardia, hypotension) with **class-dependent metabolic effects** (impaired glucose control, weight gain). The latter require agent substitution, not just dose adjustment. [cite:Harrison 21e Ch 297]